Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition.
about
Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virusA novel human immunodeficiency virus type 1 protein, tev, shares sequences with tat, env, and rev proteinsSPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanismsMolecular evolution of HIV-1 CRF01_AE Env in Thai patientsProduction of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.How does HIV-1 infect a susceptible human cell?: Current thinkingA human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand.Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. The Italian-Ugandan Cooperation AIDS Program.Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.The "V3" domain is a determinant of simian immunodeficiency virus cell tropism.Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humansAutologous antibody response against the principal neutralizing domain of human immunodeficiency virus type 1 isolated from infected humansBoth the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation.Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibodyDetailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategiesAnalysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibodyAnalysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site.Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzeesAntibodies that neutralize human beta interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping.Variability and immunogenicity of caprine arthritis-encephalitis virus surface glycoproteinNaturally occurring mutations within 39 amino acids in the envelope glycoprotein of maedi-visna virus alter the neutralization phenotypeInduction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate.Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.
P2860
Q27485919-658BDB06-4718-4FE0-AB48-15161ED0CFBDQ28246228-466A1B40-1681-40EA-A04B-8323286028C4Q28368122-88D7BEAF-990E-48F7-984C-3323EFEE92E6Q34071790-7EDD4CC1-AEF2-4DFD-ABFC-4BEA1B0148A7Q34097650-33366349-861C-4087-8AB1-FEF0FC159C7BQ35217312-1547CEB5-C3F0-4C00-B720-DCB7069FD8D6Q35828898-D37B8F2A-957F-4BC6-A7B0-5975CA96C437Q35844007-3D6E3865-1ECA-4567-A3FA-775EDDE4423DQ35852493-33438ACF-CC19-44BB-8FD5-403F6A6212E2Q36365085-48127357-443D-4577-A4A9-AAF408408BC4Q36366296-C27398C4-EB46-422E-BE64-60AF0607A31BQ36634149-FD65D1CC-6A40-4602-8B90-F80EB724ECA6Q36641374-AE888C6B-F9CE-451E-83E5-159A100DC3D6Q36644253-46134122-B2E7-46FA-8DC9-F5284956ED97Q36647416-AFEF2181-493C-4C52-AB61-8C91C07A95F4Q36687562-583175A9-9AFB-4220-B2AD-AFBF419678E3Q36690394-9BF67691-036B-4F24-B942-C65D85DBA617Q36782627-66466D65-6D5E-44C7-8EC8-C76687A46563Q36795889-46816CC6-489F-4094-B573-E7460A4C1F3FQ36811030-49F096B2-2215-4C2B-8224-DD273178EC23Q36811962-F774D9F1-C411-4C6D-8099-9A47A1476399Q37506898-E8436BF9-D936-43CA-940F-67EB59C3059BQ39591825-FB5CFB1B-BB36-4657-8FE8-6FFA1A980F46Q39595739-6770EE7E-6EBE-47B0-9D1C-C66B61ECB848Q39603619-B19577D9-3FEC-4F52-B7B9-DF437E16F373Q39868309-36C98284-17FF-4712-A8B7-25A8A9153529
P2860
Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh-hant
name
Human antibody response to a s ...... d with cell fusion inhibition.
@en
Human antibody response to a s ...... d with cell fusion inhibition.
@nl
type
label
Human antibody response to a s ...... d with cell fusion inhibition.
@en
Human antibody response to a s ...... d with cell fusion inhibition.
@nl
prefLabel
Human antibody response to a s ...... d with cell fusion inhibition.
@en
Human antibody response to a s ...... d with cell fusion inhibition.
@nl
P2093
P1433
P1476
Human antibody response to a s ...... d with cell fusion inhibition.
@en
P2093
Boucher CA
Epstein LG
Goudsmit J
van der Hoek L
P304
P407
P577
1988-06-01T00:00:00Z